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CLINICAL TRIAL
Randomized trial of intermittent
intraputamenal glial cell line-derived
neurotrophic factor in Parkinson’s disease
Alan Whone,1,2 Matthias Luz,3 Mihaela Boca,2 Max Woolley,4 Lucy Mooney,2 Sonali Dharia,2
Jack Broadfoot,2 David Cronin,2 Christian Schroers,2 Neil U. Barua,2 Lara Longpre,3
C. Lynn Barclay,3 Chris Boiko,3 Greg A. Johnson,3 H. Christian Fibiger,3 Rob Harrison,4
Owen Lewis,4 Gemma Pritchard,4 Mike Howell,4 Charlie Irving,4 David Johnson,4
Suk Kinch,4 Christopher Marshall,5 Andrew D. Lawrence,6 Stephan Blinder,7 Vesna Sossi,7
A. Jon Stoessl,8 Paul Skinner,4 Erich Mohr3 and Steven S. Gill2,4
We investigated the effects of glial cell line-derived neurotrophic factor (GDNF) in Parkinson’s disease, using intermittent intra-
putamenal convection-enhanced delivery via a skull-mounted transcutaneous port as a novel administration paradigm to poten-
tially afford putamen-wide therapeutic delivery. This was a single-centre, randomized, double-blind, placebo-controlled trial.
Patients were 35–75 years old, had motor symptoms for 5 or more years, and presented with moderate disease severity in the
OFF state [Hoehn and Yahr stage 2–3 and Uniﬁed Parkinson’s Disease Rating Scale motor score (part III) (UPDRS-III) between 25
and 45] and motor ﬂuctuations. Drug delivery devices were implanted and putamenal volume coverage was required to exceed a
predeﬁned threshold at a test infusion prior to randomization. Six pilot stage patients (randomization 2:1) and 35 primary stage
patients (randomization 1:1) received bilateral intraputamenal infusions of GDNF (120 mg per putamen) or placebo every 4 weeks
for 40 weeks. Efﬁcacy analyses were based on the intention-to-treat principle and included all patients randomized. The primary
outcome was the percentage change from baseline to Week 40 in the OFF state (UPDRS-III). The primary analysis was limited to
primary stage patients, while further analyses included all patients from both study stages. The mean OFF state UPDRS motor
score decreased by 17.3  17.6% in the active group and 11.8  15.8% in the placebo group (least squares mean difference:
4.9%, 95% CI: 16.9, 7.1, P = 0.41). Secondary endpoints did not show signiﬁcant differences between the groups either. A post
hoc analysis found nine (43%) patients in the active group but no placebo patients with a large clinically important motor
improvement (510 points) in the OFF state (P = 0.0008). 18F-DOPA PET imaging demonstrated a signiﬁcantly increased
uptake throughout the putamen only in the active group, ranging from 25% (left anterior putamen; P = 0.0009) to 100%
(both posterior putamina; P5 0.0001). GDNF appeared to be well tolerated and safe, and no drug-related serious adverse
events were reported. The study did not meet its primary endpoint. 18F-DOPA imaging, however, suggested that intermittent
convection-enhanced delivery of GDNF produced a putamen-wide tissue engagement effect, overcoming prior delivery limitations.
Potential reasons for not proving clinical beneﬁt at 40 weeks are discussed.
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Introduction
Parkinson’s disease is the second most common neurode-
generative disorder (de Lau and Breteler, 2006). Current
treatment options are symptomatic and do not prevent dis-
ease progression. Over time, patients accrue both motor
and cognitive disability and develop complications of dopa-
minergic therapies (Rascol et al., 2011).
Glial cell line-derived neurotrophic factor (GDNF) is a
potent neurotrophic protein for dopaminergic and other
neurones (Lin et al., 1993; Airaksinen and Saarma, 2002)
and shows robust neurorestorative and neuroprotective ef-
fects in nonhuman primate models of Parkinson’s disease
when administered to targets within the CNS (Gash et al.,
1996; Zhang et al., 1997; Grondin et al., 2002; Allen et al.,
2013). In patients with Parkinson’s disease, intracerebro-
ventricular administration of GDNF did not show clinical
beneﬁt (Kordower et al., 1999; Nutt et al., 2003). In two
open-label studies using continuous intraputamenal infu-
sion, GDNF substantially improved motor function at 6
and 12 months (Gill et al., 2003; Slevin et al., 2005), asso-
ciated with a focal increase in 18F-DOPA uptake at the site
of infusion in posterior putamen (Gill et al., 2003).
Moreover, single-case reports suggested dopaminergic
sprouting (Love et al., 2005) and clinical beneﬁt years
beyond end of treatment (Patel et al., 2013). The favour-
able clinical outcome, however, could not be replicated in a
randomized, placebo-controlled study using a similar infu-
sion scheme over 6 months (Lang et al., 2006).
The observed outcome discrepancies were possibly due to
insufﬁcient GDNF exposure across the putamen, since con-
tinuous low-rate infusions enable only diffusion-dependent,
irregular (heterogeneous), spatially restricted distribution
(Salvatore et al., 2006). Much wider, homogeneous distribu-
tion can be achieved with convection-enhanced delivery
(CED) which, however, requires high infusion rates that in
turn necessitate intermittent rather than continuous adminis-
tration to avoid tissue ‘ﬂooding’ (Gimenez et al., 2011). The
above, together with recent reports on striatal pharmacokin-
etics and pharmacodynamics of GDNF (Hadaczek et al.,
2010; Taylor et al., 2013), was the rationale for conducting
a randomized, placebo-controlled, study of GDNF, adminis-
tered on an intermittent (every 4 weeks) basis, in a manner
to achieve CED across the putamen. The present study was
the ﬁrst clinical study worldwide to evaluate the effects of
GDNF (or any other drug) when given via intermittent
(every 4 weeks), bilateral, intraputamenal CED.
Dosing in the context of intermittent CED is complex
and involves several dimensions, including infusion rate,
infusion volume, drug concentration, dosing interval and
total (or cumulative) dose over time. The infusion rate
and volume were chosen to achieve intraputamenal CED.
The intermittent dosing information available at the begin-
ning of the study was mostly limited to reports on striatal
pharmacokinetics and pharmacodynamics of GDNF in rats
(Hadaczek et al., 2010; Taylor et al., 2013). The infusate
GDNF concentration administered was 2-fold higher than
in the Lang investigation (0.2 mg/ml versus 0.1mg/ml) (Lang
et al., 2006); however, moving from continuous to every 4-
week intermittent dosing means the total dose delivered
over 4 weeks (240 mg) is 3.5-fold smaller than the dose
most widely used in the historic continuous dosing studies
(840 mg). Previously, unexpected clinically silent cerebellar
toxicity was observed when very high GDNF doses
(2800 mg/4 weeks, translating to a human equivalent dose
of 42 000mg/4 weeks) were given via continuous intraputa-
menal infusion in a 6-month toxicity study in rhesus mon-
keys (Hovland et al., 2007). Therefore, to ensure patient
safety, the GDNF dosing scheme used in the present study
was purposefully low. The associated risk of underdosing
was acknowledged but deemed acceptable. Additional dose
groups were not feasible ﬁnancially and logistically in this
single-centre investigator-initiated study.
Because of a lack of commercially-available drug delivery
devices that would facilitate intermittent infusions to the
brain parenchyma over an extended time period, a novel
in-house system was speciﬁed by the lead neurosurgeon
(Lewis et al., 2016). Most importantly, the system included
a skull-mounted transcutaneous port allowing for non-in-
vasive repeat infusions via four separate microcatheters.
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Although a ﬁrst-in-man device in its entirety, key device
performance features and device attributes such as long-
term catheter patency, controlled infusions and device
safety had been developed previously (Bienemann et al.,
2012; Barua et al., 2013, 2016; Gill et al., 2013).
Altogether, the study entered uncharted territory in sev-
eral areas. The study results, while of primary relevance to
GDNF and Parkinson’s disease, were considered potentially
useful for other applications and indications where direct,
targeted drug delivery to brain parenchyma could be bene-
ﬁcial. The primary hypothesis being tested was that GDNF,
if administered in a manner to permit CED across the pu-
tamen, would achieve neurorestoration leading to clinically
signiﬁcant beneﬁt.
Materials and methods
Study design and structure
This single-centre, placebo-controlled, randomized, double-
blind, parallel-group trial of intermittent bilateral intraputame-
nal infusions of GDNF administered via CED was performed
in two stages. The pilot stage (n = 6) served to assess the safety
of the surgical technique and study drug administration, and
to optimize planned study procedures. The primary stage
(n = 35) was initiated upon completion of a prespeciﬁed
safety review of the pilot patients after 12 weeks of treatment.
All patients randomized and completing study treatment after
40 weeks had the option to enrol in a subsequent open-label
extension study which will be reported separately.
Blocked, web-based randomization with a block size of six
was used to randomize patients between GDNF and diluent,
artiﬁcial CSF, which served as placebo. Randomization was
performed by the Bristol Randomised Trials Collaboration,
University of Bristol, at a site separate to the investigating
site. The randomization ratio was 2:1 in the pilot stage and
1:1 in the primary stage. Patients and investigators were
masked to treatment allocation. Ready-to-use preparations of
GDNF and artiﬁcial CSF were visually identical. To further
protect against bias, motor scoring was performed by trained
raters blinded to all other aspects of the patient’s condition,
and GDNF plasma concentrations and anti-GDNF serum anti-
bodies were assayed only after the study was completed.
Local institutional and ethical committee approval was ob-
tained and all patients provided written informed consent accord-
ing to the Declaration of Helsinki. The Trial Steering Committee
and an independent Data Monitoring Committee provided clin-
ical oversight. The authors vouch for the accuracy and complete-
ness of the data and for adherence to the study protocol (see
Supplementary material, part A, for study protocol ﬁrst and
ﬁnal versions as well as a summary of protocol amendments).
Patients
Between October 2012 and April 2015, 196 subjects from
throughout the UK were prescreened, of whom 64 patients
with bilateral idiopathic Parkinson’s disease according to the
UK Brain Bank Criteria underwent full study screening (see
Supplementary material, part B, for CONSORT ﬂow
diagram). All study visits were performed at North Bristol
Trust, Bristol, UK (Frenchay Hospital site until May 2014,
Southmead Hospital site thereafter), except for the PET
scans, which were acquired at the Wales Research and
Diagnostic PET Imaging Centre, Cardiff, UK and analysed at
the PET Imaging Centre of the University of British Columbia,
Vancouver, BC, Canada.
Patients were eligible for implantation surgery if they were
35 to 75 years old, on stable anti-parkinson medication for
56 weeks and presented with motor symptom duration 55
years, moderate disease severity [Hoehn and Yahr stage 2–3
and Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) motor
score (part III) between 25 and 45, both in a practically-
deﬁned OFF state], motor ﬂuctuations (average of at least
2.5 h of OFF time per day on 3-day ﬂuctuation diaries), and
levodopa responsiveness deﬁned as 540% improvement in
UPDRS motor score following a levodopa challenge. Main
exclusion criteria were: atypical parkinsonian syndromes,
family history of 41 ﬁrst-degree relative with Parkinson’s dis-
ease, moderate depression (Beck Depression Inventory 420),
clinically signiﬁcant impulse control disorder, cognitive decline
[Montreal Cognitive Assessment (MoCA) 524], and increased
risk of surgery. Once implanted with the drug delivery system,
patients were randomized if they had no relevant sequelae
from surgery and demonstrated 540% coverage of a prede-
ﬁned volume of interest in the motor putamen on a gadolin-
ium-enhanced test infusion.
Study procedures and assessments
After screening, eligible patients underwent robot-assisted sur-
gery for stereotactic implantation of the customized in-house
CED system comprising four separate infusion catheters and a
single skull-mounted transcutaneous port (Fig. 1A and B; for
device background summary and patient infusion images, see
Supplementary material, parts C and D, respectively). Four
weeks post-operatively, catheter patency and infusate distribu-
tion were assessed by T1-weighted MRI following an intrapu-
tamenal test infusion of 2mM solution of gadolinium in
artiﬁcial CSF (Fig. 1C). If sufﬁcient (540%) volume of interest
coverage was conﬁrmed on the MRI scan, patients proceeded
to randomization.
Post-randomization, patients received a total of 10 study
treatments at 4-week intervals (Weeks 0 to 36). At each treat-
ment, 400 ml of infusate (300ml GDNF or placebo, followed by
100 ml artiﬁcial CSF) were delivered per catheter. The infusate
GDNF concentration was 0.2 mg/ml, and the total GDNF dose
given every 4 weeks was 240 mg (120 mg/putamen).
The protocol stated that Parkinson’s disease medication was
to be kept stable during the study where possible but could be
modiﬁed if required for symptom control.
Every 8 weeks post-randomization, starting with the baseline
visit at Week 0, prior to infusions, patients completed 3-day
diary recordings and underwent assessment of motor function
in the practically deﬁned OFF state and following a levodopa
challenge. Other efﬁcacy outcome measures were assessed at
baseline and Week 40. Samples for GDNF plasma concentra-
tions and anti-GDNF serum antibodies were collected through-
out the study. At Week 40, all patients underwent a repeat test
infusion of gadolinium-enhanced artiﬁcial CSF followed by
T1-weighted MRI to determine maintenance of infusate
delivery.
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All patients underwent baseline 18F-DOPA PET scanning be-
tween randomization and baseline assessments prior to the
start of treatment (see Supplementary material, part E, for
PET methodology). A further 18F-DOPA PET scan was per-
formed at the end of the study, 2 weeks after the last study
infusion.
Study outcomes
The primary endpoint of the study was percentage change
from baseline in the practically-deﬁned OFF state UPDRS
motor score (part III) after 40 weeks of double-blind
treatment.
Secondary endpoints included percentage change from base-
line to Week 40 in UPDRS motor score in the ON state, as
well as percentage change from baseline in UPDRS activities of
daily living (ADL; part II) and total (sum of motor and ADL)
scores in the OFF and ON state, UPDRS parts I and IV, and
change from baseline to Week 40 in Parkinson’s disease diary
ratings. Supplementary efﬁcacy endpoints included timed
motor tests in both OFF and ON state, total daily levodopa
and levodopa equivalent dose, the Non-Motor Symptom Scale
for Parkinson’s disease (NMSS), cognitive, mood and impul-
sivity measures, the University of Pennsylvania Smell
Identiﬁcation Test (UPSIT) and Parkinson-related quality of
life questionnaires (PDQ-39 and EQ-5D). Patients’ satisfaction
and impact on quality of life in relation to the delivery device
were not speciﬁcally explored.
Post-screening, assessment of UPDRS motor and ADL
scores, timed taps and timed walks were completed by three
trained raters who were blinded to all other aspects of the
patient’s condition. Wherever possible, the same rater that per-
formed the baseline assessment also performed the Week 40
assessment. All OFF assessments were performed at a similar
time in the morning, following withholding of long-acting anti-
Parkinson medications the day before and all other anti-
Parkinson’s disease medications from 6pm the evening before.
During screening, patients were trained on the completion of
the Parkinson’s disease diary and had to demonstrate their
ability to accurately determine their ON/OFF state as part of
the inclusion criteria.
Imaging endpoints included change from baseline to Week
40 in gadolinium-evidenced volume of infusate distribution,
volume of interest coverage and total putamenal coverage as
assessed on T1-weighted MRIs, and in
18F-DOPA uptake, as
well as correlations between clinical outcome, gadolinium-
based coverage and change in 18F-DOPA uptake.
Safety was assessed on the basis of adverse events, routine
laboratory testing and anti-GDNF serum antibodies.
Treatment-emergent adverse events (TEAEs) were deﬁned as
adverse events starting on or after the date of the ﬁrst dose
of randomized study medication. Dyskinesias, falls, adverse
changes in mood, and impulsivity were summarized as
Figure 1 Method of drug administration. (A) Drug delivery system used in the study. A manikin view of the delivery system is shown.
Externally, when infusions are delivered, a titanium application set is attached to a skull-mounted port. The application set houses four inde-
pendent external lines that feed back to four independent B. Braun pumps (not shown) for the administration of GDNF or placebo. Internally,
from the skull mounted port, run four independent catheters. (B) The skull-mounted port is the only external component when the patient is not
receiving an infusion. (C) Gadolinium test infusion. An axial MRI section at the level of the striatum is shown. Two of the four catheters (dorsal
two catheters) can be seen entering either side of the brain posteriorly to penetrate the putamen. T1 imaging has been acquired post a test
infusion of 2 mM gadolinium down the catheters and into each putamen. Gadolinium can be seen distributed through both putamen from the
rostral to caudal extent. (D) A single patient during infusion. (E) Three patients receiving their monthly intraputamenal infusions from B. Braun
pumps via their skull-mounted ports, in a standard day-case facility, observed by an accompanying nurse.
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TEAEsof special interest. In addition, patients were monitored
for cognitive function (MoCA and Mattis Dementia Rating
Scale) and signs of impulsive or compulsive behaviour
(Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s disease).
Statistical analysis
Statistical analyses, as prespeciﬁed in the statistical analysis
plan (see Supplementary material, part F, for ﬁrst and ﬁnal
versions of statistical analysis plan as well as a summary of
statistical analysis plan amendments), were conducted with the
use of Statistical Analysis System (SAS) software, version 9.4
(SAS Institute). Any hypothesis testing was performed with a
2-sided alternative at an alpha level of 0.05. No adjustments
for multiplicity were made. Sample size was calculated on the
basis of the primary endpoint, assuming a standard deviation
(SD) of 20%, a 2-sided type I error of 5%, a power of 80%,
and a difference of 20 points in percentage change in OFF
state UPDRS motor score from baseline.
Efﬁcacy analyses were based on the intention-to-treat prin-
ciple and included patients randomized after reaching prespe-
ciﬁed post-surgical eligibility criteria. As the pilot stage served
to optimize planned study procedures, it was anticipated a
priori that relevant differences between patients at the two
stages might emerge during the study. Therefore, the primary
analysis was limited to primary stage patients (n = 35). Further
prespeciﬁed efﬁcacy analyses were also performed on all pa-
tients from both study stages (n = 41). A mixed-effect model
with repeated measures (MMRM) adjusted for the baseline
value was used for the comparison of treatment groups in
the primary analysis. Sensitivity analyses of the primary end-
point also included analyses of covariance (ANCOVA) instead
of the MMRM. Secondary and supplementary efﬁcacy end-
points were analysed using either the MMRM or an
ANCOVA model adjusted for the baseline value of the respect-
ive assessment. Non-parametric Spearman rank correlation
analyses were used to test for potential correlations between
clinical endpoints and imaging endpoints, and between MRI
and PET imaging endpoints. No corrections for multiple com-
parisons were made, and a hierarchical approach to the sec-
ondary endpoints was not employed.
Safety was generally evaluated in the overall population
including patients from both study stages to make maximum
use of the available safety information post-randomization.
Additional safety analyses were performed to evaluate the oc-
currence of adverse events in the peri-surgical period prior to
both randomization and start of treatment.
A post hoc analysis plan was devised after the ﬁnal study
results became available (Supplementary material, part G). It
included analyses of UPDRS motor score subscales, magnitude
of motor response, phenotypic covariates and additional ima-
ging endpoints in the overall population. Again, no corrections
for multiple comparisons were made.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding authors, upon reasonable request.
Results
Patients
The 35 primary stage patients had a mean (SD) age of
56.4  7.9 years (range: 41–72), and a mean disease dur-
ation since ﬁrst symptom of 10.9  5.3 years. Except for
gender, other demographic and baseline Parkinson’s disease
characteristics were similar between treatment groups
(Table 1).
Drug delivery
Catheters were positioned accurately with a mean distance
between planned and actual target for catheter tips of
0.6  0.5mm (range: 0.0–2.0mm). Mean putamenal gado-
linium-evidenced coverage on MRI showed only small dif-
ferences between hemispheres, treatment groups and time
points. Between all of these variables, it ranged from
67.1  15.3% to 78.5  14.2% for the putamenal
volume of interest and from 47.8  13.5% to
55.0  17.1% for total putamen.
With 347 (99.1%) of 350 scheduled study drug infusions
administered, compliance with infusion visits over the study
period was high. Altogether, 9 (5.4%) of 167 GDNF infu-
sions and 10 (5.6%) of 180 placebo infusions were inter-
rupted or terminated early. Misalignment of the application
set connector to the skull-mounted port was thought to
account for early termination of four infusions in each
group. The remaining interruptions or early terminations
were typically related to a single catheter and nearly
always occurred as an automatic safety pump shut-down
Table 1 Demographic and Parkinson’s disease
characteristics at screening
Characteristic GDNF
(n = 17)
Placebo
(n = 18)
Age, years 57.7  8.2 55.1  7.5
Male sex, n (%) 7 (41.2) 11 (61.1)
Race, n (%)
White 17 (100) 17 (94.4)
Asian 0 1 (5.6)
OFF-state Hoehn and Yahr stage, n (%)
Stage 2 8 (47.1) 5 (27.8)
Stage 2.5 4 (23.5) 8 (44.4)
Stage 3 5 (29.4) 5 (27.8)
Disease duration, years
Since first motor symptom 10.8  5.0 10.9  5.8
Since original diagnosis 8.6  4.3 7.9  3.7
UPDRS motor score
OFF state 37.1  7.2 35.8  6.1
ON state 16.9  5.2 16.9  4.5
Levodopa response, %a 54.2  9.4 52.8  9.4
OFF-time per day, h 6.3  2.2 6.1  2.1
aPercentage improvement in UPDRS motor score following a levodopa challenge.
516 | BRAIN 2019: 142; 512–525 A. Whone et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/3/512/5365284 by U
niversity of Bristol Library user on 04 June 2019
response to transient high catheter pressure, which did not
translate to any adverse events for the participants. Two
occluded infusion channels were identiﬁed at the test infu-
sion stage, in response to which a double volume dose was
then prescribed down the ipsilateral putamenal catheter for
all study infusions in those two subjects, in line with the
study protocol.
Clinical outcomes
Between baseline and Week 40, mean OFF state UPDRS
motor scores decreased by 17.3  17.6% (6.2  7.1 abso-
lute points, from 35.3  9.4 to 29.1  10.3 points) in the
GDNF group and 11.8  15.8% (3.4  4.3 absolute
points, from 32.2  8.7 to 28.8  9.8 points) in the pla-
cebo group, with no statistically signiﬁcant mean treatment
difference in favour of GDNF at any of the 8-weekly time
points during the study (least squares mean difference:
4.9%, 95% CI: 16.9, 7.1, P = 0.41; Table 2 and
Fig. 2A). None of the sensitivity analyses showed a statis-
tically signiﬁcant treatment effect in favour of GDNF,
which included an assessment of the primary endpoint
using the overall population from both study stages
(n = 41; least squares mean difference: 8.4%, 95% CI:
19.3, 2.5; P = 0.13). No patients dropped out or were
excluded post randomization.
Analysis of secondary endpoints at Week 40, including
percentage change from baseline in UPDRS motor score in
the ON state, UPDRS ADL and total scores in both OFF
and ON state, and UPDRS parts I and IV, as well as
change from baseline in Parkinson’s disease diary ratings,
did not reveal any signiﬁcant difference between the GDNF
and placebo treated groups (Table 2). While the primary
and secondary results were generally favouring GDNF nu-
merically, the mean UPDRS ADL score in the ON stage
was numerically in favour of placebo. This was due pri-
marily to two subjects who showed large percentage in-
creases from small baseline values (367%, 14 versus 3
points; and 200%, 3 versus 1 points). Consistent with
this, the absolute mean scores in the GDNF group were
identical at baseline and at Week 40 (6.3).
Supplementary efﬁcacy endpoints including timed motor
tests in both OFF and ON state, total daily levodopa and
levodopa equivalent dose, the NMSS, cognitive, mood and
impulsivity measures, the UPSIT and quality of life ques-
tionnaires did not reveal any signiﬁcant difference between
the GDNF and placebo treated groups (Table 2).
To investigate the magnitude of motor response, a post
hoc analysis testing for absolute improvement by 55
points or 510 points in the OFF state UPDRS motor
score was performed in the overall population from both
study stages. The analysis showed no difference between
GDNF and placebo with the 55-point cut-off [13 (62%)
versus 13 (65%); P4 0.50] but a signiﬁcant difference in
favour of GDNF with the 510-point cut-off [9 (43%)
versus 0; P = 0.0008; not corrected for multiple
comparisons]. Figure 2B. shows the frequency distribution
of motor responses in both groups.
Post hoc covariate analyses adjusting for demographic
and Parkinson’s disease characteristics (see post hoc statis-
tical analysis plan) did not identify any speciﬁc clinical fea-
tures producing change in treatment effect on the primary
endpoint.
PET outcomes
The PET ﬁndings at baseline were consistent with the
known rostro-caudal gradient of neurodegenerative
changes in the striatum of patients with Parkinson’s
disease (Stoessl, 2011). Accordingly, the highest mean
18F-DOPA uptake rate constants (Kocc, expressed as
102min1) at baseline were found in the caudate nucleus,
and the lowest values were found in posterior putamen
(Table 2 and Fig. 3).
Between baseline and Week 40, mean Kocc remained
unchanged in all regions in the placebo group. In contrast,
in the GDNF group, mean Kocc increased by 100% (from
0.3  0.1 to 0.6  0.2) in posterior putamen (left and right
side, P5 0.0001 versus placebo), 50% (left side: from
0.6  0.2 to 0.9  0.3) to 60% (right side: from
0.5  0.2 to 0.7  0.2) in central putamen (P5 0.0001
versus placebo), and 25% (left side: from 0.8  0.3 to
1.0  0.3) to 29% (right side: from 0.7  0.2 to
0.9  0.2) in anterior putamen (P = 0.0009 and 0.0001,
respectively, versus placebo) (Table 2 and Fig. 3). No sig-
niﬁcant correlations were seen in either treatment group
between percentage change from baseline to Week 40 in
OFF state UPDRS motor score and alteration from baseline
to Week 40 in 18F-DOPA Kocc in any of the putamenal
regions assessed.
Data available from prior published PET studies indicate
that a normal Kocc control value would be 1.0 in both
caudate and putamen, and a value of 0.6 (seen in posterior
putamen following treatment) would be similar to what
would be expected following recent symptom onset (Sossi
et al., 2003).
Safety
TEAEs were reported for all 41 patients (Table 3). No pa-
tient had a TEAE leading to discontinuation of study medi-
cation. TEAEs that occurred more frequently in the GDNF
group than in the placebo group (difference of 53 patients
between treatment groups) included dyskinesia, paraesthe-
sia, Lhermitte’s sign, ON and OFF phenomena, and diplo-
pia. The overall frequency of TEAEs of special interest was
similar in both treatment groups (GDNF: 62%, placebo:
55%).
Serious TEAEs were reported for ﬁve (24%) GDNF pa-
tients and no placebo patients; all were unrelated to study
medication: device-related events (three), pyelonephritis
(one), complications from conus injury following a car
accident (one). The three serious TEAEs that were
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considered to be device related included two occurrences
of hypertrophic skin reaction around the port site that
required surgical skin thinning (11 and 25 weeks
into the treatment phase, respectively) and a possible
port site infection that occurred 15 weeks into the treat-
ment phase and required inpatient treatment with oral
antibiotics.
The picture of device-related adverse events in general
was dominated by port site infections and local
hypertrophic scarring around the port site; many of these
emerged in the post-surgical pretreatment period.
Education in the study population to promote port-site
device maintenance, similar to that used by patients with
bone-anchored hearing aids, evolved and improved as the
study progressed. No intracranial infections occurred
during the study. A minor alteration to the original port
design at the beginning of the primary stage resulted in port
loosening in the ﬁrst six patients implanted in the primary
Table 2 Efficacy outcomes
Outcome category
Variable
GDNF (n = 17) Placebo (n = 18) Least squares mean
difference versus
placebo (95% CI); P
Baseline Week 40 Change, (%) Baseline Week 40 Change, (%)
UPDRS (part) scores
Motor (III) OFF 35.3  9.4 29.1  10.3 17.3  17.6 32.2  8.7 28.8  9.8 11.8  15.8 4.9% (16.9, 7.1); 0.41*
Motor (III) ON 17.4  5.0 16.3  6.3 4.3  33.4 16.6  7.5 17.8  8.4 8.8  21.7 12.2% (31.6, 7.1); 0.21*
ADL (II) OFF 18.4  6.3 16.0  7.0 12.2  26.9 16.9  6.1 16.2  5.5 1.0  26.6 9.3% (27.8, 9.2); 0.31*
ADL (II) ON 6.3  4.2 6.3  4.0 30.4  109.9 5.7  3.6 5.8  4.1 1.5  49.4 33.1% (24.2, 90.4); 0.25*
Total (II + III) OFF 54.3  13.8 45.9  15.3 15.2  16.5 49.1  11.6 45.0  12.9 9.2  10.3 5.2% (15.2, 4.8); 0.30*
Total (II + III) ON 23.6  7.5 22.6  9.1 0.3  41.2 22.3  8.9 23.7  10.5 6.0  19.0 5.2% (27.0, 16.6); 0.63*
Timed tapping, n
OFF state 42.7  14.1 54.4  16.4 11.7  7.1 41.8  9.5 51.4  15.7 9.6  11.0 2.1 (4.4, 8.6); 0.51*
ON state 60.5  16.1 69.8  16.7 9.3  7.6 58.6  14.8 66.4  16.9 7.8  9.2 1.6 (4.3, 7.4); 0.59*
Timed walking, s
OFF state 52.6  65.2 24.2  34.0 23.9  47.6 18.2  11.3 17.0  15.8 4.8  8.5 4.0 (11.2, 19.2); 0.59*
ON state 11.5  2.7 11.2  2.0 0.3  1.6 10.6  2.0 10.1  1.8 0.4  1.2 0.6 (0.2, 1.5); 0.14*
Motor fluctuation diary ratings, h
Total OFF time 6.1  1.8 5.1  2.4 1.0  1.9 4.8  2.3 5.0  2.5 0.4  2.1 1.0 (2.4, 0.4); 0.17*
Good quality ON time 10.3  2.1 11.4  3.3 1.3  1.9 12.5  2.7 12.1  2.6 0.4  1.9 1.2 (0.3, 2.7); 0.13*
ON time with troublesome
dyskinesias
0.5  1.1 0.4  1.3 0.1  1.2 0.5  1.0 0.4  1.1 0.1  0.5 0.0 (0.6, 0.7); 0.92*
Total daily dose, mg
L-DOPA 671  333 655  300 16  212 569  298 614  306 45  113 43 (155, 70); 0.44**
L-DOPA equivalent 1,019  377 1,026  408 8  234 978  392 1,077  410 100  156 89 (227, 48); 0.19**
Non-motor outcomes
NMSS total score 38.7  22.7 23.7  18.9 15.0  21.2 38.3  31.1 30.4  28.3 7.9  21.2 6.9 (19.9, 6.1); 0.29*
PDQ-39 single index 25.4  12.7 26.0  15.4 0.6  10.5 28.5  15.4 23.1  13.9 5.4  8.7 5.4 (1.2, 12.0); 0.11**
18F-DOPA uptake (Kocc), 102 min1
Anterior putamen lt. 0.8  0.3 1.0  0.3 0.2  0.2 0.8  0.2 0.7  0.2 0.0  0.1 0.2 (0.1, 0.3); 0.0009**
Anterior putamen rt. 0.7  0.2 0.9  0.2 0.2  0.2 0.6  0.2 0.6  0.2 0.0  0.1 0.2 (0.1, 0.3); 50.0001**
Central putamen lt. 0.6  0.2 0.9  0.3 0.3  0.2 0.5  0.2 0.6  0.2 0.0  0.1 0.3 (0.2, 0.4); 50.0001**
Central putamen rt. 0.5  0.2 0.7  0.2 0.3  0.2 0.4  0.1 0.4  0.1 0.0  0.1 0.3 (0.2, 0.4); 50.0001**
Posterior putamen lt. 0.3  0.1 0.6  0.2 0.3  0.2 0.3  0.1 0.3  0.1 0.0  0.1 0.3 (0.2, 0.3); 50.0001**
Posterior putamen rt. 0.3  0.1 0.6  0.1 0.3  0.1 0.3  0.1 0.3  0.1 0.0  0.1 0.3 (0.2, 0.4); 50.0001**
Caudate lt. 1.1  0.2 1.0  0.3 0.0  0.1 1.0  0.2 0.9  0.2 0.0  0.1 0.0 (0.1, 0.1); 0.79**
Caudate rt. 1.0  0.3 1.0  0.3 0.0  0.1 0.9  0.2 0.9  0.2 0.0  0.1 0.0 (0.0, 0.1); 0.24**
*MMRM with baseline variable as a covariate, treatment group and visit and treatment group  visit as fixed effects, and patient within treatment group as a random effect.
**ANCOVA model with baseline variable as a covariate and treatment group as a factor.
One GDNF patient had a conus injury due to a car accident and was included in the UPDRS motor scores without items 22 and 27–30. The same patient was excluded from the
UPDRS ADL and total scores. Timed tapping numbers are averages of left and right. UPDRS parts I and IV, EQ-5D, body weight, Simplified Nutritional Appetite Questionnaire,
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease, Montreal Cognitive Assessment, Mattis Dementia Rating Scale, Stroop test, Frontal Systems Behavioral
Scale, Deary-Liewald reaction time, verbal fluency assessment, Beck Depression Inventory, and University of Pennsylvania Smell Identification Test remained essentially unchanged
between baseline and Week 40 in both groups and did not reveal any significant treatment differences between GDNF and placebo. For the assessment of 18F-DOPA uptake, single
position dynamic PET scans were acquired as 26 time frames over 94.5 min (1  30 s, 4  1 min, 3  2 min, 3  3 min, and 15  5 min) in a GE Discovery 690 PET/CT (GE
Healthcare). The tissue input function was estimated from the time course of the radioactivity concentration in regions of interest placed on the occipital cortex. Analysis occurred
following established procedures as previously described by Nandhagopal et al. (2009). One GDNF patient was included in the Week 40 analyses of 18F-DOPA uptake although the
final PET scan was performed 2 days in advance of the visit window specified in the statistical analysis plan.
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stage. This was rectiﬁed prior to treatment initiation by the
introduction of a retro-ﬁt device for ﬁrm ﬁxation of the
port in the affected patients and all subsequently enrolled
patients.
Two enrolled patients did not proceed to randomization
and were withdrawn prior to the start of treatment because
they failed the post-surgery eligibility criteria; accordingly,
they were not included in the efﬁcacy analyses. One patient
experienced a mildly symptomatic putamenal ischaemic
stroke coincident with the initial test infusion. The patient
recovered completely but was withdrawn to avoid unneces-
sary risks. The second patient suffered a small asymptom-
atic haemorrhage in both putamina during the initial test
infusion. Subsequent observations of developing repeat
gadolinium test infusions, using real-time MRI sequencing,
indicated limited volume of interest coverage, which pre-
vented the subject from being randomized. This was
likely caused by haemorrhage-induced alterations restrict-
ing the retrograde ﬂow of the infusate back along the cath-
eter track into the desired target region. It is possible that
the haemorrhage may have resulted from ejection of tissue
debris collected within the catheter during the implantation.
Following this occurrence, additional intraoperative cath-
eter ﬂushing was introduced as a routine step during
device implantation, with no further issues observed in re-
maining subjects.
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Figure 2 OFF state UPDRS motor score. (A) OFF state UPDRS motor score: percentage change over time. Note that data points
represent means, and error bars represent standard errors. One GDNF patient had a conus injury due to a car accident and was included in the
motor score without items 22, 27, 28, 29, and 30. The P-value is from a MMRM for the percentage change from baseline to Week 40 between
treatment groups. (B) Frequency distribution of change from baseline to Week 40 in OFF state UPDRS motor score (intention-to-treat overall
population = primary stage and pilot stage patients, n = 41).
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Blood sample analyses showed no measurable GDNF
plasma concentrations and no GDNF-binding serum anti-
bodies in GDNF-treated patients.
Discussion
Reversing neurodegenerative disease remains one of the
greatest medical challenges. Neurotrophic factors are
among the most promising candidate therapies, with
demonstrated neuroprotective and neurorestorative capabil-
ities in animal models of Parkinson’s disease (Allen et al.,
2013). One major difﬁculty in translating these ﬁndings
into the clinic has been to ﬁnd a way of delivering the
agents across the blood–brain barrier to meaningful vol-
umes within relevant brain targets and potentially over
the remaining lifetime of the patient. Here we show for
the ﬁrst time that this challenge has been met with the
development of a long-term implantable drug delivery
system that facilitates intermittent intraparenchymal infu-
sions for an extended time period.
However, in this double-blind trial of 41 randomized pa-
tients with moderate stage Parkinson’s disease, 40 weeks of
ﬁxed-dose GDNF intraputamenal infusions (120 mg GDNF
in 600 ml artiﬁcial CSF to each putamen), administered
every 4 weeks, did not produce a signiﬁcantly larger per-
centage improvement than placebo in OFF state UPDRS
motor score, the primary study outcome. In addition, no
signiﬁcant improvements over placebo were observed in
any of the secondary or exploratory motor endpoints, nor
in any of the non-motor or quality of life endpoints. In
contrast to the main clinical ﬁndings, serial PET imaging
revealed a signiﬁcant increase in 18F-DOPA uptake in the
GDNF group but not the placebo group, which was spa-
tially extensive and suggested whole putamen target tissue
delivery.
The essence of our clinical ﬁndings is consistent with an
earlier randomized, placebo-controlled trial of GDNF in
Parkinson’s disease (Lang et al., 2006), although the
latter used continuous diffusion-dependent intraputamenal
delivery resulting in spatially limited putamen delivery
(Salvatore et al., 2006). In aggregate, therefore, these two
studies raise the question as to whether the underlying
growth factor hypothesis is ﬂawed, or whether the hypoth-
esis per se is correct but the clinical testing in both studies
has been ﬂawed and further evaluation is required, in-
formed by this investigation and its follow-on open-label
extension.
The regenerative effects of GDNF in Parkinson’s disease
have been questioned by studies using a rat model with
overexpression of human wild-type -synuclein. In this
model, targeted delivery of GDNF to the striatum failed
to prevent loss of nigral dopamine neurones or their ter-
minals in the striatum (Decressac et al., 2011). A subse-
quent investigation suggested that Nurr1, a regulator of
neurotrophic factor signalling, as well as its downstream
target, GDNF receptor component RET, are decreased in
the presence of excess -synuclein (Decressac et al., 2012).
In other words, the intracellular signalling response
to GDNF may be blocked in the presence of excess
-synuclein. A recent study, however, found that SNCA
(-synuclein) mRNA is not increased in sporadic
Parkinson’s disease, and -synuclein accumulation does not
block GDNF signalling in either Parkinson’s disease or
Parkinson’s disease models (Su et al., 2017). Consistent
with these ﬁndings, the integrity of the GDNF signalling
Figure 3 Representative 18F-DOPA images from two patients, shown at baseline and end of double blind study. Top: Images are
from a patient who was receiving placebo infusions every 4 weeks; 10 placebo infusions in total. Bottom: Images are from a patient who was
receiving GDNF infusions every 4 weeks; 10 GDNF infusions in total.
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cascade in our patients is supported by the signiﬁcant puta-
menal increase in 18F-DOPA uptake at Week 40.
Independent of the -synuclein question, it is conceivable
that mostly toxin-based, static preclinical models may not
be representative of the progressive human disease. This is
contradicted, however, by ﬁndings in a single patient in an
early open-label phase I study who was treated with GDNF
for 43 months via a unilateral continuous intraputamenal
infusion and died from myocardial infarction after the
study (Love et al., 2005). The patient had unilateral disease
on the left and was therefore treated on the right, leaving
the contralateral side as an intra-patient control. At 24
months, the patient showed appreciable clinical beneﬁt on
the left coupled with improved 18F-DOPA uptake in the
right posterior putamen. This was contrasted by a small
decrease in 18F-DOPA uptake on the left and new-onset
motor symptoms on the right in the latter part of the treat-
ment. Post-mortem ﬁndings showed dopaminergic sprout-
ing in the posterior third of the right putamen and greater
expression of tyrosine hydroxylase (TH) on the right than
on the left. Consistent with the clinical laterality, the net
loss of dopaminergic neurons in the substantia nigra was
greater on the right than on the left. At the same time,
presumably in response to treatment with GDNF, the
nigral expression of GAP43 and synaptophysin was also
greater on the right.
If, therefore, the growth factor hypothesis is still valid,
the question about the limitations of the clinical studies
becomes pertinent. These include: Can this potential treat-
ment only be effective in early stage disease where innerv-
ation of the striatum with dopaminergic neurons is
maintained above a critical threshold? Was the dose of
GDNF selected for this study sufﬁcient? Was the treatment
duration long enough? Could patient phenotype, placebo
effects or methods of assessment have played a part?
Ethical considerations limited recruitment in the present
study to patients with moderate stage Parkinson’s disease.
The failure to demonstrate clinical beneﬁt at 40 weeks may
be the consequence of recruiting patients too late in their
disease. A recent post-mortem study showed that within 4
years post-diagnosis, patients with Parkinson’s disease had
an almost complete loss of TH-positive terminals and dopa-
mine transporter immunohistochemistry in the dorsal puta-
men (Kordower et al., 2013). However, these ﬁndings may
reﬂect neuron hibernation and not just neuron death alone.
Potentially in favour of hibernation, GDNF-treated patients
in the present study, where the mean time from diagnosis
was 8 years, showed a signiﬁcant increase in putamenal
18F-DOPA uptake throughout the putamen with no or little
differences in absolute improvement between the anterior,
mid and posterior regions of interest. If the ﬁndings of the
Kordower study were reﬂective of neurone death alone, the
increase in the posterior third of the putamen, the locus of
greatest reduction in TH in Parkinson’s disease, would per-
haps have been expected to be smaller than in the anterior
putamen. The hibernation hypothesis is also supported by
the post-mortem improvements in the posterior putamen
observed in the above phase I patient whose treatment
commenced 5 years after diagnosis (Love et al., 2005).
Ethical considerations also limited the duration of the
present study to 9 months to avoid an undue length of
exposure to placebo in a surgical setting. However, 9
months may have been too short a period of repeated
putamenal tissue GDNF exposure to achieve adequate
functionality of reconnecting neurons. It is possible
that there is a lag between a biomarker effect such as
18F-DOPA uptake and clinical improvement. Further in-
sight into this question may, in part, be provided by the
open-label extension study.
Other potential limitations are associated with drug de-
livery and dose. Drug distribution in the previous,
continuous low-rate infusion clinical studies was diffu-
sion-dependent, heterogeneous, and spatially restricted to
less than 10% total putamenal coverage (Salvatore et al.,
2006). This could explain the observed lack of clinical
beneﬁt in the earlier phase II double blind study (Lang
et al., 2006). The intermittent CED dosing scheme used
Table 3 Treatment-emergent adverse events
experienced by at least three patients of a treatment
group (overall population from both study stages)
Adverse event GDNF
(n = 21) n (%)
Placebo
(n = 20) n (%)
Patients with at least one TEAE 21 (100) 20 (100)
Dyskinesia 9 (43) 5 (25)
Paresthesia 8 (38) 2 (10)
Lhermitte’s sign 8 (38) 0
ON and OFF phenomena 7 (33) 2 (10)
Nasopharyngitis 6 (29) 8 (40)
Headache 6 (29) 7 (35)
Application site infection 5 (24) 2 (10)
Fall 4 (19) 6 (30)
Freezing phenomenon 4 (19) 3 (15)
Muscle spasms 4 (19) 3 (15)
Constipation 4 (19) 1 (5)
Dizziness 4 (19) 1 (5)
Pain in extremity 4 (19) 1 (5)
Cough 3 (14) 4 (20)
Application site erythema 3 (14) 3 (15)
Pre-existing condition improved 3 (14) 3 (15)
Fatigue 3 (14) 2 (10)
Urinary tract infection 3 (14) 2 (10)
Lethargy 3 (14) 1 (5)
Nausea 3 (14) 1 (5)
PD-related symptoms 3 (14) 1 (5)
Diarrhea 3 (14) 0
Diplopia 3 (14) 0
Back pain 2 (10) 5 (25)
Drug effect decreased 2 (10) 4 (20)
Head injury 2 (10) 4 (20)
Joint injury 2 (10) 4 (20)
Application site pain 1 (5) 4 (20)
Insomnia 1 (5) 3 (15)
Impulsive behaviour 0 3 (15)
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in the present study led to much wider distribution, sup-
ported by the gadolinium-evidenced coverage of putamenal
volume of interest (67.1–78.5%) and total putamen (47.8–
55.0%) over 40 weeks as well as the putamen-wide in-
crease in 18F-DOPA uptake in GDNF-treated patients. In
contrast, as the dosing information available at the begin-
ning of the study was sparse, a conservative approach was
taken to dose, so as to avoid any unnecessary safety risk in
view of the cerebellar lesions that were unexpectedly
observed in several rhesus monkeys treated with very
high GDNF doses (Hovland et al., 2007). Due to the
switch from continuous to intermittent dosing, the cumula-
tive 4-week dose per putamen in the present study was 3.5-
fold smaller than in the historic continuous dosing studies
(120 mg versus 420 mg), albeit the infusate GDNF concen-
tration was twofold higher (0.2 mg/ml versus 0.1 mg/ml).
Considering the combination of 5-fold larger putamenal
coverage and 3.5-fold smaller cumulative 4-week doses, the
resulting tissue GDNF concentrations in the exposed vol-
umes were 18-fold lower in the present study. As retro-
grade transportation of GDNF from the putamen to the
substantia nigra is known to be concentration-dependent
(Aoi et al., 2000), it is therefore possible that whilst the
tissue GDNF concentrations were sufﬁcient to induce a
PET-evidenced biological effect, they were too low to pro-
duce clinical beneﬁt within 40 weeks. This would be sup-
ported by the fact that a post hoc analysis of nigral 18F-
DOPA uptake did not show any differences between treat-
ment groups (data not shown), whereas a noticeable in-
crease was seen in the only continuous-dosing study that
assessed nigral 18F-DOPA uptake (Gill et al., 2003).
Clinically, the present study found numerical mean differ-
ences in favour of GDNF in all OFF state motor and
Parkinson’s disease diary-based endpoints at all time
points, and a post hoc responder analysis showed that sig-
niﬁcantly more patients on GDNF than on placebo had a
moderate-to-large clinically important change in OFF state
motor score (Shulman et al., 2010). While in the absence of
statistically signiﬁcant results for the primary and second-
ary endpoints, inferences are of course speculative, one po-
tential explanation for these ﬁndings is that underdosing
played a part.
It is also worth noting that the key preclinical studies that
were used to derive the clinical dose demonstrated that
both the pharmacokinetics and the pharmacodynamics of
intrastriatally infused GDNF were dependent on infusate
GDNF concentrations (Hadaczek et al., 2010; Taylor
et al., 2013). In particular, the Taylor study showed that
while a signiﬁcant increase in striatal synaptogenesis (as
determined by synaptophysin concentration) was observed
at an infusate GDNF concentration of 0.2mg/ml, maximal
axonal sprouting only occurred at 0.6 mg/ml (Taylor et al.,
2013). However, the latter concentration is very close to
the concentration used in the rhesus monkeys that de-
veloped cerebellar lesions (0.67 mg/ml), and was therefore
considered too high at the time (Hovland et al., 2007).
Meanwhile, a further 9-month toxicity study testing the
intermittent dosing paradigm in rhesus monkeys has estab-
lished 0.67 mg/ml as the no-observed-adverse-effect level
(Luz et al., 2018), thus opening the door to include this
threefold higher dose level in future clinical studies.
A potential confounder of the present study was the mag-
nitude of the placebo effect. While similar to that seen in
other surgical studies in Parkinson’s disease (Olanow,
2005; Goetz et al., 2008; Marks et al., 2010), it was not-
ably larger than in the earlier phase II double blind study
that had been used as the main point of reference when
estimating the sample size (Lang et al., 2006). Conceivably,
the 4-weekly visit schedule, in concert with dedicated clin-
ical care at a single site committed to maximize patient
retention, the prospect of receiving active drug at the end
of the study, and investigator bias may have contributed to
the observed placebo response. However, the earlier phase
II double blind study also included an optional open-label
extension, and other structural differences between the stu-
dies are relatively subtle considering the magnitude and
consistency of the placebo response across different clinical
endpoints. Therefore, it is worth considering that putame-
nal tissue disruption as a result of catheter implantation
and repeated high-pressure CED infusions may have
played a part. It is known that striatal injury, primarily
via a GDNF- and BDNF-dependent mechanism mediated
by activated macrophages and microglia, leads to strong
and potentially persistent stimulation of the nigrostriatal
dopamine system (Batchelor et al., 1999, 2000; Liberatore
et al., 1999). Associated with the amount of trauma that
was appreciably larger in the present study than in the
earlier phase II double blind study (two catheters per pu-
tamen versus one, longitudinal versus vertical putamenal
trajectories, and continuous low-rate, low-pressure infu-
sions versus intermittent high-rate, high-pressure infusions),
these self-repair effects may have been more pronounced in
the present study. Although they would presumably have
been associated with an increase in 18F-DOPA uptake that
was not noted in the placebo group, nevertheless it seems
possible that an intermittent placebo CED arm produces
effects beyond those of a traditional surgical placebo arm.
Two further limitations of the study include the residual
effect of symptomatic medication and the sample size.
Although we used the commonly agreed deﬁnition of the
practically deﬁned OFF state (all OFF assessments were
performed at a similar time in the morning, following with-
holding of long-acting anti-parkinson medications the day
before and all other anti-parkinson medications from 6pm
the evening before), we recognize that the true ‘wash out’
period for all dopaminergic drugs including long acting
agonists exceeds the standard withdrawal period allowed
by this paradigm. The sample size was small despite the
study being adequately powered to detect signiﬁcant
change in the primary outcome, and we recognize this as
a further limitation to interpreting the study results.
The nine 10-point responders in the GDNF group are a
potential focus of interest; however, as this a post hoc
ﬁnding we would not wish to over-interpret its meaning.
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As shown in Fig. 2B, absolute changes in UPDRS motor
score demonstrated a fairly even spread across subjects in
the active arm from minimal worsening in score to greater
than 10-point improvements. In other words, a bimodal
distribution of absolute responders versus absolute non-re-
sponders was not seen. Furthermore, post hoc covariate
analyses investigating phenotypic characteristics such as
age, disease duration, disease severity, tremor predomin-
ance etc. did not identify a subtype of patients predicting
an enhanced beneﬁt. The nine 10-point responders did not
differ in surgical approach, drug delivery or maintenance of
their delivery systems, infusate volumes of distribution on
MRI scans or magnitude of 18F-DOPA PET response.
At this point, therefore, we are not able to identify a
priori a particular subgroup of Parkinson’s patients that
are either more or less likely to respond to GDNF therapy.
That said, it may be that some patients require longer dur-
ation of GDNF exposure to experience clinical beneﬁt than
others, therefore creating the appearance of responders
versus non-responders with a 40-week infusion
programme.
In contrast to our clinical outcomes, serial 18F-DOPA
PET imaging revealed a signiﬁcant increase in radioligand
uptake in the GDNF group. This increase was meaningful
in effect size, present throughout the putamen and notably
higher than in prior Parkinson’s disease trophic factor stu-
dies (Lang et al., 2006; Marks et al., 2008, 2010). The
earlier phase II double blind study used continuous infu-
sions via abdominal pumps with subsequent diffusion-de-
pendent putamenal distribution and therefore, showed
increased PET signal uptake predominantly around the
catheter tips (Lang et al., 2006). With the intermittent
CED approach, however, signiﬁcant change was seen
throughout the putamen, with a percentage gradient of
increased improvement from posterior to anterior putamen,
but not affecting the non-infused caudate, in keeping with a
true biological effect of the treatment.
The increase in 18F-DOPA signal could indicate terminal
sprouting, reawakening of hibernating terminals, an upre-
gulation of aromatic amino acid decarboxylase, or a com-
bination of all three (Moore et al., 2003). It is important to
appreciate that 18F-DOPA is trapped by all monoaminergic
neuron types, and hence, the contribution from nigral
dopaminergic versus raphe serotonergic terminal change
cannot be differentiated (Moore et al., 2003). Moreover,
it cannot be conﬁrmed that such change results in restor-
ation of dopamine neurone function. For this, any potential
future investigation would need to include additional ima-
ging outcomes, such as using dopamine neuron-speciﬁc
radiotracers and raclopride displacement assessments
(Piccini et al., 1999; Kaasinen and Vahlberg, 2017).
Comparing with prior investigations, it is worth noting
that the biological effect was sufﬁcient to move absolute
18F-DOPA PET Kocc uptake values from those typically
associated with moderate to advanced disease to those
seen in mild Parkinson’s disease (Sossi et al., 2003). This
contrasts with the prior clinically negative viral vector
neurturin studies in Parkinson’s disease, where no PET
signal beneﬁt was observed (Marks et al., 2008, 2010).
Despite the marked relative percentage increase, the abso-
lute caudal putamen uptake values at Week 40 remain ap-
proximately half that of normal control and perhaps to
achieve clinical beneﬁt the absolute level of PET signal im-
provement needs to be yet higher (Sossi et al., 2003).
Previous foetal graft studies, which also showed a mis-
match between 18F-DOPA uptake improvement and nega-
tive clinical outcomes, are not necessarily a mirror of our
ﬁndings, as in these studies it was the grafted tissue that
accounted for the enhanced radiotracer trapping rather
than biological alteration within the endogenous terminal
plexus per se (Olanow et al., 2003). Indeed, a recent post-
mortem examination performed 16 years after foetal graft-
ing showed TH innervation indistinguishable from normal
and yet clinical beneﬁt was not observed (Kordower et al.,
2017). We fully acknowledge that the history of disease-
modifying studies in Parkinson’s disease contains similar
examples of achieving signiﬁcant 18F-DOPA imaging im-
provements while failing to achieve clinical outcomes
(Cochen et al., 2003; Whone et al., 2003; Mittermeyer
et al., 2012). This study, we believe, is yet further evidence
that for disease-modifying studies the ﬁeld to-date does not
have an adequate clinical outcome correlating biomarker.
Patient safety was reviewed with regard to both drug and
drug delivery device. As in previous studies using continu-
ous infusion schemes (Gill et al., 2003; Slevin et al., 2005;
Lang et al., 2006), GDNF appeared to be well tolerated
and safe. There were no serious adverse events related to
the study drug. GDNF-related adverse events included dys-
kinesia and ON/OFF phenomena, but without the problem-
atic diphasic dyskinesias reported in a previous foetal graft
trial (Olanow et al., 2003). It cannot be excluded that
Lhermitte’s phenomena and paraesthesia that occurred at
higher rates in GDNF-treated patients may have led to par-
tial unblinding. In contrast to the earlier phase II double
blind study (Lang et al., 2006), no GDNF-binding serum
antibodies in GDNF-treated patients were found in the pre-
sent study.
Regarding the device, it is important to note that it was
an in-house system developed for this trial. The 140 micro-
catheters implanted into the primary stage population were
delivered into the putamen safely with an operational ac-
curacy of 0.6  0.5mm (range: 0.0–2.0mm). In total, 417
infusion cycles amounting to 1668 individual catheter infu-
sions were delivered in the study.
The majority of device-related adverse events were port
site-associated, most commonly local hypertrophic scarring
or infections, amenable to antibiotics. The frequency of
these declined during the trial as surgical and device hand-
ling experience improved. No conﬁrmed intracranial infec-
tions occurred. Test infusions to demonstrate adequate
infusate delivery, prior to randomization, produced a
minor stroke in one patient that subsequently fully
resolved, and an asymptomatic haemorrhage in another
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leading to a persistent change in the implantation tech-
nique. Neither subject was subsequently randomized.
Treatment infusions post randomization were consist-
ently asymptomatic during administration. Catheter sys-
tems remained patent during the 9-month treatment
period except for one blocked infusion channel in each
treatment group. This was thought to be due to ﬁlter oc-
clusion and was compensated for by doubling the infusion
volume through the paired catheter on the same side.
In conclusion, we have conducted the ﬁrst randomized
trial in Parkinson’s disease to use CED to administer a
trophic factor to the putamen on an every-4-weeks basis
via a skull-mounted port. Recruiting patients from across
the UK and delivering study treatment on an outpatient
basis, this trial shows that, independent from conclusions
on GDNF, attending for monthly putamenal infusions of a
putative neurorestorative therapy is feasible and tolerable.
This study, therefore, marks a potential paradigm shift in
direct-target delivery of future novel therapies as they
become available, for a host of neurological conditions.
As evidenced by increased 18F-DOPA PET signal, we
have shown that this method of administration affords a
spatial delivery of GDNF sufﬁcient to achieve a biological
effect across the entire putamen. At the 40-week point,
however, we have not shown clinical beneﬁt despite this
putamen-wide tissue engagement. Future GDNF investiga-
tions will need to address potential reasons why our clinical
primary endpoint was not reached despite apparently opti-
mizing putamenal therapeutic delivery. The open-label ex-
tension study, to be reported separately, providing a further
40 weeks of therapy, may offer evidence on the impact of
longer time-duration tissue exposure on clinical outcomes.
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